Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20625250 | 0.86 | GAA (0.51) | CYP1A2CYP2D6MAPTPOLBCYP2C9 | |
| SCHEMBL313843 | 0.86 | MAPT (0.48) | CYP1A2CYP2D6MAPTPOLBCYP2C9 | |
| SCHEMBL8484189 | 0.85 | FAAH (0.62) | CYP1A2CYP2D6MGLL | |
| SCHEMBL31677693 | 0.85 | CYP1A2 (0.48) | CYP1A2CYP2D6MGLL | |
| Hydrochloric Acid SCHEMBL16694536 | 0.85 | ALDH1A1 (0.47) | CYP1A2CYP2D6MAPTPOLBCYP2C9 | |
| SCHEMBL6136613 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2D6MAPTPOLBCYP2C9 | |
| SCHEMBL2803614 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2D6MAPTPOLBCYP2C9 | |
| SCHEMBL2722317 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2D6MAPTPOLBCYP2C9 | |
| SCHEMBL2803619 | 0.83 | ALDH1A1 (0.58) | CYP1A2CYP2D6MAPTMGLLALDH1A1 | |
| SCHEMBL22806633 | 0.83 | CYP1A2 (0.46) | CYP1A2CYP2D6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | CYP1A2 814/4885CYP2D6 528/4885MAPT 3212/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | CYP1A2 479/4885CYP2D6 263/4885MAPT 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.